CN113301914B - 用于治疗和预防纤维化的组合物和方法 - Google Patents

用于治疗和预防纤维化的组合物和方法

Info

Publication number
CN113301914B
CN113301914B CN201980086450.8A CN201980086450A CN113301914B CN 113301914 B CN113301914 B CN 113301914B CN 201980086450 A CN201980086450 A CN 201980086450A CN 113301914 B CN113301914 B CN 113301914B
Authority
CN
China
Prior art keywords
leu
gly
asn
ala
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980086450.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113301914A (zh
Inventor
韩忠成
禹东勋
金�雄
李在勋
安根豪
俞宅镇
郑镇宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nyhill Co ltd
Original Assignee
Nyhill Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180128033A external-priority patent/KR102129178B1/ko
Priority claimed from KR1020180128204A external-priority patent/KR102129179B1/ko
Priority claimed from KR1020180128625A external-priority patent/KR102161892B1/ko
Application filed by Nyhill Co ltd filed Critical Nyhill Co ltd
Publication of CN113301914A publication Critical patent/CN113301914A/zh
Application granted granted Critical
Publication of CN113301914B publication Critical patent/CN113301914B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
CN201980086450.8A 2018-10-25 2019-10-24 用于治疗和预防纤维化的组合物和方法 Active CN113301914B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
KR10-2018-0128204 2018-10-25
KR10-2018-0128033 2018-10-25
KR1020180128033A KR102129178B1 (ko) 2018-10-25 2018-10-25 심근경색 예방 또는 치료용 재조합 단백질을 포함하는 심근경색 예방 또는 치료용 조성물
KR1020180128204A KR102129179B1 (ko) 2018-10-25 2018-10-25 알츠하이머병 예방 또는 치료용 재조합 단백질을 포함하는 알츠하이머병 예방 또는 치료용 조성물
KR1020180128625A KR102161892B1 (ko) 2018-10-26 2018-10-26 특발성 폐섬유증 예방 또는 치료용 재조합 단백질을 포함하는 특발성 폐섬유증 예방 또는 치료용 조성물
KR10-2018-0128625 2018-10-26
PCT/IB2019/001136 WO2020084344A2 (en) 2018-10-25 2019-10-24 Compositions and methods for treating or preventing fibrosis

Publications (2)

Publication Number Publication Date
CN113301914A CN113301914A (zh) 2021-08-24
CN113301914B true CN113301914B (zh) 2026-02-03

Family

ID=70331794

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980086450.8A Active CN113301914B (zh) 2018-10-25 2019-10-24 用于治疗和预防纤维化的组合物和方法

Country Status (5)

Country Link
US (2) US12139518B2 (https=)
EP (1) EP3870210A4 (https=)
JP (2) JP7659499B2 (https=)
CN (1) CN113301914B (https=)
WO (1) WO2020084344A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7659499B2 (ja) * 2018-10-25 2025-04-09 ネクセル カンパニー，リミテッド 線維症を治療又は予防するための組成物及び方法
MX2022002638A (es) 2019-09-06 2022-03-25 Novartis Ag Proteinas de fusion terapeuticas.
KR102801198B1 (ko) * 2021-06-28 2025-04-30 (주) 넥셀 특발성 폐섬유증 예방 또는 치료용 폴리펩타이드 및 이를 포함하는 약학 조성물
KR102758046B1 (ko) * 2021-11-05 2025-01-23 (주) 넥셀 궤양성 대장염 예방 또는 치료용 재조합 단백질 및 이를 포함하는 궤양성 대장염 예방 또는 치료용 조성물
CN118633748A (zh) * 2024-05-29 2024-09-13 哈尔滨工业大学 一种包含乳源mfg-e8的产品及其在改善衰老、学习和/或记忆障碍中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109689098A (zh) * 2016-07-21 2019-04-26 医福斯治疗有限公司 包括具有fc结合能力的融合蛋白的胞外囊泡的用途
CN114341195A (zh) * 2019-09-06 2022-04-12 诺华股份有限公司 治疗性融合蛋白

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972337A (en) 1990-11-01 1999-10-26 Cancer Research Fund Of Contra Costa 46 kilodalton human milk fat globule (HMFG) antigen, fragments and fusion protein
EP1004664A1 (en) 1998-11-24 2000-05-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods using lactadherin or variants thereof
IL160142A0 (en) * 2001-08-17 2004-06-20 Anosys Inc Methods and compounds for the targeting of protein to exosomes
JP4160292B2 (ja) * 2001-11-20 2008-10-01 独立行政法人科学技術振興機構 生体内のアポトーシス細胞の除去促進剤及び除去阻害剤
WO2010096713A2 (en) * 2009-02-20 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for the diagnosis of age-associated vascular disorders
JP2014507649A (ja) * 2011-01-18 2014-03-27 バクスター・インターナショナル・インコーポレイテッド ヒト血液中の抗βアミロイド抗体の測定
EP3021942A4 (en) * 2013-07-19 2017-04-19 The Regents of The University of California Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
WO2015025956A1 (ja) 2013-08-22 2015-02-26 国立大学法人九州大学 心筋障害治療用薬剤組成物、心筋障害予防用薬剤組成物、心不全治療用薬剤組成物、心不全予防用薬剤組成物、心筋障害又は心不全を治療又は予防する方法、ｍｆｇ－ｅ８、ｍｆｇ－ｅ８の使用、及び心筋障害又は心不全を治療又は予防する化合物のスクリーニング方法
AU2016260190A1 (en) 2015-05-12 2017-11-23 The Regents Of The University Of California Peptide treatment for inflammation and fibrosis
KR20170013621A (ko) * 2015-07-28 2017-02-07 (주) 넥셀 Ｍｉｌｋ ｆａｔ ｇｌｏｂｕｌｅ－ＥＧＦ ｆａｃｔｏｒ（ＭＦＧ－Ｅ８）을 이용한 조직섬유화 예방 또는 치료용 조성물
CN105288592A (zh) 2015-11-02 2016-02-03 哈尔滨博翱生物医药技术开发有限公司 成纤维细胞生长因子-21成熟肽在制备肝纤维化治疗药物中的应用
KR102129178B1 (ko) 2018-10-25 2020-07-01 (주) 넥셀 심근경색 예방 또는 치료용 재조합 단백질을 포함하는 심근경색 예방 또는 치료용 조성물
KR102129179B1 (ko) 2018-10-25 2020-07-01 (주) 넥셀 알츠하이머병 예방 또는 치료용 재조합 단백질을 포함하는 알츠하이머병 예방 또는 치료용 조성물
KR101947902B1 (ko) 2017-05-17 2019-02-13 (주) 넥셀 간 섬유화 예방 또는 치료용 재조합 단백질 및 이를 포함하는 간 섬유화 예방 또는 치료용 조성물
KR102161892B1 (ko) 2018-10-26 2020-10-05 (주) 넥셀 특발성 폐섬유증 예방 또는 치료용 재조합 단백질을 포함하는 특발성 폐섬유증 예방 또는 치료용 조성물
JP7659499B2 (ja) 2018-10-25 2025-04-09 ネクセル カンパニー，リミテッド 線維症を治療又は予防するための組成物及び方法
CN118076371A (zh) 2021-04-22 2024-05-24 百进生物科技公司 用于检测和耗竭磷脂酰丝氨酸阳性细胞的磷脂酰丝氨酸结合剂
KR102758046B1 (ko) 2021-11-05 2025-01-23 (주) 넥셀 궤양성 대장염 예방 또는 치료용 재조합 단백질 및 이를 포함하는 궤양성 대장염 예방 또는 치료용 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109689098A (zh) * 2016-07-21 2019-04-26 医福斯治疗有限公司 包括具有fc结合能力的融合蛋白的胞外囊泡的用途
CN114341195A (zh) * 2019-09-06 2022-04-12 诺华股份有限公司 治疗性融合蛋白

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Liu,W.等.lactadherin isoform a preproprotein [Homo sapiens].Genbank Database.2025,Accession No： NP_005919.2. *
MFG-E8与冠心病的关系研究进展;王迪;韦传东;;医学综述;20200113(第02期);第219-223页 *
Two Alternative Mechanisms That Regulate the Presentation of Apoptotic Cell Engulfment Signal in Caenorhabditis elegans;Victor Venegas等;Molecular Biology of the Cell;20070831;对比文件1第3181-3182页，图1 *
Victor Venegas等.Two Alternative Mechanisms That Regulate the Presentation of Apoptotic Cell Engulfment Signal in Caenorhabditis elegans.Molecular Biology of the Cell.2007,对比文件1第3181-3182页，图1. *

Also Published As

Publication number Publication date
US20250115649A1 (en) 2025-04-10
WO2020084344A3 (en) 2020-07-16
JP2022509445A (ja) 2022-01-20
CN113301914A (zh) 2021-08-24
WO2020084344A2 (en) 2020-04-30
EP3870210A2 (en) 2021-09-01
US20210388041A1 (en) 2021-12-16
JP7659499B2 (ja) 2025-04-09
JP2024133483A (ja) 2024-10-02
EP3870210A4 (en) 2022-10-19
US12139518B2 (en) 2024-11-12

Similar Documents

Publication Publication Date Title
CN113301914B (zh) 用于治疗和预防纤维化的组合物和方法
Aoki et al. Attenuation of bleomycin-induced pulmonary fibrosis by follistatin
KR20100099249A (ko) 세포막 재봉합을 조절하기 위한 조성물 및 방법
CN112168969B (zh) Ddit4l及其功能小肽对胶质母细胞瘤的抑制作用
JP5122278B2 (ja) 眼細胞生存の促進におけるラクリチンの使用
US20170218082A1 (en) Human soluble cd146, preparation and uses thereof
TW202142254A (zh) 用於治療或預防纖維化、肥大或心臟衰竭之骨髓源性生長因子
EP2734220A2 (en) Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis
You et al. Dynein-mediated nuclear translocation of yes-associated protein through microtubule acetylation controls fibroblast activation
US9273116B2 (en) Fusion protein comprising albumin and retinol-binding protein
JP2004154140A (ja) 血管形成及び心血管新生の促進又は阻害
JP2003531811A5 (https=)
CN101505780B (zh) 发育相关疾病的治疗
JP2009019032A (ja) 血管形成及び心臓血管新生の促進又は阻害
US20130316958A1 (en) Highly potent peptides to control cancer and neurodegenerative diseases
Liu et al. The CCL20–integrin α5β1 interaction enhances TGF-β/Smad signaling to promote fibroblast activation in pulmonary fibrosis
Hu et al. Calcium and integrin binding protein 1 (CIB1) induces myocardial fibrosis in myocardial infarction via regulating the PI3K/Akt pathway
EP1255829B1 (en) Inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization
Moritz et al. Macrophage TGF-β1 and the proapoptotic extracellular matrix protein BIGH3 induce renal cell apoptosis in prediabetic and diabetic conditions
Richards et al. Haploinsufficiency of Casitas B-Lineage Lymphoma augments the progression of colon cancer in the background of adenomatous polyposis coli inactivation
US20140066360A1 (en) Methods for using semaphorin polypeptides
CN113748123B (zh) 用于治疗肺部炎症的组合物
KR20010085792A (ko) 혈관형성 및 심혈관형성의 촉진 또는 억제
JP7723955B2 (ja) 筋線維芽細胞を脱活性化するためのＴｃｆ２１タンパク質の部分ペプチド
EP4378472A1 (en) Therapeutic agent for ischemic disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant